BioXcel Therapeutics to be Acquired by Kindred Biosciences Affiliate
Ticker: BTAI · Form: 8-K · Filed: Aug 15, 2025 · CIK: 1720893
Sentiment: neutral
Topics: acquisition, merger, biotech
TL;DR
BioXcel is getting bought by Kindred Biosciences affiliate, deal expected Q4 2025.
AI Summary
BioXcel Therapeutics, Inc. announced on August 14, 2025, that it has entered into a definitive agreement to be acquired by an affiliate of Kindred Biosciences, Inc. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions. This acquisition will combine two companies focused on developing innovative therapies.
Why It Matters
This acquisition signals a consolidation within the biotechnology sector, potentially impacting the development and availability of therapies for both human and animal health.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, and the success of the integration and future development of combined therapies are not guaranteed.
Key Players & Entities
- BioXcel Therapeutics, Inc. (company) — Registrant and target company
- Kindred Biosciences, Inc. (company) — Acquiring entity's affiliate
- August 14, 2025 (date) — Date of the definitive agreement
- fourth quarter of 2025 (date) — Expected closing period of the acquisition
FAQ
What is the primary purpose of this Form 8-K filing?
This Form 8-K filing is to report the "Other Events" related to BioXcel Therapeutics, Inc. entering into a definitive agreement to be acquired.
Who is acquiring BioXcel Therapeutics, Inc.?
BioXcel Therapeutics, Inc. is being acquired by an affiliate of Kindred Biosciences, Inc.
When is the acquisition expected to close?
The acquisition is expected to close in the fourth quarter of 2025.
What are the conditions for the acquisition to close?
The acquisition is subject to customary closing conditions.
What is the principal executive office address for BioXcel Therapeutics, Inc.?
The principal executive office address is 555 Long Wharf Drive, New Haven, CT 06511.
Filing Stats: 438 words · 2 min read · ~1 pages · Grade level 11.1 · Accepted 2025-08-15 09:18:51
Key Financial Figures
- $0.001 B — ch registered Common Stock, par value $0.001 BTAI The Nasdaq Capital Market Indic
Filing Documents
- tm2523368d3_8k.htm (8-K) — 24KB
- 0001104659-25-079042.txt ( ) — 184KB
- btai-20250814.xsd (EX-101.SCH) — 3KB
- btai-20250814_lab.xml (EX-101.LAB) — 33KB
- btai-20250814_pre.xml (EX-101.PRE) — 22KB
- tm2523368d3_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On August 14, 2025, BioXcel Therapeutics, Inc. (the "Company") received positive preliminary meeting comments from the U.S. Food and Drug Administration (FDA) related to the pre-sNDA meeting scheduled for August 20, 2025. The Company is evaluating the feedback from the FDA and plans to provide an update next week. The primary purpose of the planned pre-sNDA meeting is to gain alignment with the FDA regarding the proposed format and content of the Company's planned sNDA submission, including the clinical, nonclinical and chemistry, manufacturing and controls (CMC) requirements.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 15, 2025 BIOXCEL THERAPEUTICS, INC. /s/ Richard Steinhart By: Richard Steinhart Title: Chief Financial Officer